financetom
Business
financetom
/
Business
/
Vision Sensing Acquisition Signs Letter of Intent to Merge With Convergence CT
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Vision Sensing Acquisition Signs Letter of Intent to Merge With Convergence CT
Aug 24, 2024 1:15 AM

05:33 PM EDT, 08/22/2024 (MT Newswires) -- Vision Sensing Acquisition ( VSAC ) , a blank-check company, said late Thursday it signed a nonbinding letter of intent to merge with Convergence CT in a deal that would take Convergence public in the US.

Under the terms of the deal, the consideration provided to Convergence equity holders will be $135 million.

Vision Sensing said details of the final deal structure will be decided before signing a binding merger agreement, expected to be completed within 45 days. The merged entity is expected to trade on the Nasdaq under a new, yet-to-be-determined ticker symbol.

Vision Sensing also said the company and Mediforum mutually agreed to terminate their planned merger deal. "The parties agreed that it would not be possible for them to complete the proposed transaction within a reasonable period of time and have waived any claims against each other," the company said.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Why Calidi Biotherapeutics (CLDI) Stock Is Down 30%
Why Calidi Biotherapeutics (CLDI) Stock Is Down 30%
Jan 10, 2025
Calidi Biotherapeutics Inc ( CLDI ) shares are trading lower by 32% to 92 cents during Friday’s session after the company priced its public offering of 5 million shares of common stock at $0.85 per share, aiming to raise approximately $4.25 million in gross proceeds. The offering is set to close on January 10, pending customary closing conditions. Ladenburg Thalmann...
Crinetics Shares Fall After Reporting 'Positive' Phase 2 Results for Congenital Adrenal Hyperplasia Treatment
Crinetics Shares Fall After Reporting 'Positive' Phase 2 Results for Congenital Adrenal Hyperplasia Treatment
Jan 10, 2025
01:19 PM EST, 01/10/2025 (MT Newswires) -- Crinetics Pharmaceuticals ( CRNX ) shares were down more than 12% Friday after the company reported positive topline results from a phase 2 trial of investigational compound atumelnant for treating classic congenital adrenal yyperplasia, or CAH, and adrenocorticotropic hormone, or ACTH-dependent Cushing's syndrome. The study, which included 28 patients across three dose groups,...
Pfizer must face lawsuit over diversity fellowship program, US court rules
Pfizer must face lawsuit over diversity fellowship program, US court rules
Jan 10, 2025
(Reuters) - A U.S. appeals court on Friday revived a lawsuit by a conservative group opposed to diversity initiatives in medicine that challenged a Pfizer ( PFE ) fellowship program designed to boost the pipeline of Black, Latino and Native American people in leadership positions at the drugmaker. At the urging of the group Do No Harm, a 2-1 panel...
Ecolab Well-Positioned for Future Growth, Faces Short-Term Challenges, RBC Says
Ecolab Well-Positioned for Future Growth, Faces Short-Term Challenges, RBC Says
Jan 10, 2025
01:21 PM EST, 01/10/2025 (MT Newswires) -- Ecolab ( ECL ) is expected to achieve stable volume and pricing growth during 2025, keeping the cleaning supplies company on track for moderate improvement, though it may still fall slightly short of consensus expectations for the next 12 months, analysts at RBC Capital Markets said in an earnings preview. For Q4, RBC...
Copyright 2023-2026 - www.financetom.com All Rights Reserved